204 related articles for article (PubMed ID: 20555063)
1. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up.
Bellmunt J; Orsola A; Maldonado X; Kataja V;
Ann Oncol; 2010 May; 21 Suppl 5():v134-6. PubMed ID: 20555063
[No Abstract] [Full Text] [Related]
2. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Glynne-Jones R; Northover JM; Cervantes A;
Ann Oncol; 2010 May; 21 Suppl 5():v87-92. PubMed ID: 20555110
[No Abstract] [Full Text] [Related]
3. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Okines A; Verheij M; Allum W; Cunningham D; Cervantes A;
Ann Oncol; 2010 May; 21 Suppl 5():v50-4. PubMed ID: 20555102
[No Abstract] [Full Text] [Related]
4. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Horwich A; Parker C; Bangma C; Kataja V;
Ann Oncol; 2010 May; 21 Suppl 5():v129-33. PubMed ID: 20555062
[No Abstract] [Full Text] [Related]
5. The treatment of advanced bladder cancer.
Sternberg CN
Ann Oncol; 1995 Feb; 6(2):113-26. PubMed ID: 7786818
[No Abstract] [Full Text] [Related]
6. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Haie-Meder C; Morice P; Castiglione M;
Ann Oncol; 2010 May; 21 Suppl 5():v37-40. PubMed ID: 20555099
[No Abstract] [Full Text] [Related]
7. Aggressive behavior of low-grade Ta papillary urothelial bladder neoplasm in a 17-year-old patient.
Labanaris AP; Labanaris PG; Gitsos G; Kühn R; Schott GE; Zugor V
Urology; 2007 May; 69(5):983.e1-2. PubMed ID: 17482953
[TBL] [Abstract][Full Text] [Related]
8. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Stahel RA; Weder W; Lievens Y; Felip E;
Ann Oncol; 2010 May; 21 Suppl 5():v126-8. PubMed ID: 20555061
[No Abstract] [Full Text] [Related]
9. Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role?
Sternberg CN
Ann Oncol; 2002; 13 Suppl 4():273-9. PubMed ID: 12401701
[No Abstract] [Full Text] [Related]
10. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
; Bellmont J; Albiol S
Ann Oncol; 2007 Apr; 18 Suppl 2():ii38-9. PubMed ID: 17491039
[No Abstract] [Full Text] [Related]
11. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of invasive bladder cancer.
Kataja VV; Pavlidis N;
Ann Oncol; 2005; 16 Suppl 1():i43-4. PubMed ID: 15888749
[No Abstract] [Full Text] [Related]
12. [Neoadjuvant chemotherapy: meta-analysis and interpretation of results in bladder cancer].
Pollera CF
Suppl Tumori; 2004; 3(4):S59-61. PubMed ID: 15206215
[No Abstract] [Full Text] [Related]
13. [Adjuvant chemotherapy after cystectomy for bladder tumors staged as superior or equal to pT3].
Schmid HP; Studer UE
Prog Urol; 1997 Feb; 7(1):102-4. PubMed ID: 9116724
[No Abstract] [Full Text] [Related]
14. Treatment of muscle-invasive bladder cancer: A systematic review.
Chou R; Selph SS; Buckley DI; Gustafson KS; Griffin JC; Grusing SE; Gore JL
Cancer; 2016 Mar; 122(6):842-51. PubMed ID: 26773572
[TBL] [Abstract][Full Text] [Related]
15. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Dreyling M;
Ann Oncol; 2010 May; 21 Suppl 5():v181-3. PubMed ID: 20555076
[No Abstract] [Full Text] [Related]
16. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Dummer R; Hauschild A; Guggenheim M; Jost L; Pentheroudakis G;
Ann Oncol; 2010 May; 21 Suppl 5():v194-7. PubMed ID: 20555080
[No Abstract] [Full Text] [Related]
17. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Casali PG; Blay JY;
Ann Oncol; 2010 May; 21 Suppl 5():v198-203. PubMed ID: 20555081
[No Abstract] [Full Text] [Related]
18. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?
Kuczyk M; Turkeri L; Hammerer P; Ravery V;
Eur Urol; 2003 Jul; 44(1):57-64. PubMed ID: 12814676
[TBL] [Abstract][Full Text] [Related]
19. Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future.
Vetterlein MW; Witjes JA; Loriot Y; Giannarini G; Albersen M; Ribal MJ; Rouprêt M;
Eur Urol Oncol; 2020 Dec; 3(6):789-801. PubMed ID: 32553706
[TBL] [Abstract][Full Text] [Related]
20. Importance of node dissection in relation to neoadjuvant and adjuvant therapy.
Huang WC; Bochner BH
J Natl Compr Canc Netw; 2006 Nov; 4(10):1019-26. PubMed ID: 17112450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
